It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The company has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39.

NASDAQ:DNLI opened at $21.25 on Friday. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33. The company has a fifty day moving average price of $24.23 and a 200 ...

And Denali (Nasdaq: DNLI) is taking a "small" equity stake as well, Tenvie leaders said. What's more, 35-employee Tenvie is subleasing 15,000 square feet from Denali in South San Francisco.

The company is advancing a pipeline of therapeutics, including programs acquired from Denali Therapeutics Inc., focused on treating neurological, cardiometabolic and ophthalmic diseases.

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tenvie Therapeutics launched today with a commitment to transform the treatment of neurological diseases. The company combines a deep and diverse portfolio of small ...

NEW YORK, NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company’s trust account ...

On Wednesday, Stifel analysts maintained a Buy rating on shares of Denali Therapeutics Inc. (NASDAQ:DNLI) with a price target of $37.00. According to InvestingPro data, analysts remain highly bullish ...

Positive results from clinical trials often give biotechnology companies a boost, but this one was big. Shares of Sana Biotechnology —a firm with a market capitalization of less than $400 million as ...